Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

PHASE3CompletedINTERVENTIONAL

Enrollment

7,372

Participants

Timeline

Start Date

November 22, 2012

Primary Completion Date

August 1, 2019

Study Completion Date

October 18, 2019

Conditions

Cervical Intraepithelial NeoplasiaCervical CancerVaginal Intraepithelial NeoplasiaVulvar Intraepithelial NeoplasiaPersistent Infection

Interventions

BIOLOGICAL

HPV Vaccine

3 doses at month 0,1 and 6

BIOLOGICAL

HEV vaccine

3 doses at month 0,1 and 6

Trial Locations (1)

Cancer Institute ＆ Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

collaborator

Ministry of Science and Technology of the People´s Republic of China

OTHER_GOV

lead

Xiamen University

OTHER

NCT01735006 - Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine | Biotech Hunter | Biotech Hunter